Luton, Bedfordshire, United Kingdom, June 05, 2025 (GLOBE NEWSWIRE) -- The global pediatric glioma drugs market is poised for substantial growth, with an estimated value of approximately USD 5 billion ...

A 51-year-old `fit and healthy’ sports teacher died within ten days of being diagnosed with a killer brain tumour. According ...

CNS Pharmaceuticals (NASDAQ: CNSP) announced that Chief Medical Officer Sandra Silberman, M.D., Ph.D., will present at the Brain Tumor Biotech Summi ...

Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and ...

Iopofosine-131 received FDA breakthrough status for relapsed or refractory Waldenstrom macroglobulinemia, showing strong ...

Impact of neuroradiologists’ input on peer review meetings for CNS radiotherapy treatment planning. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include ...

Fit sports teacher dies 10 days after glioma diagnosis. Learn early warning signs of this aggressive brain cancer.

Real-world experience with vorasidenib in IDH-mutant gliomas: Tolerability, adverse events, and access in patients who did not meet INDIGO trial eligibility criteria. This is an ASCO Meeting Abstract ...

For patients with diffuse gliomas, tumor-related epilepsy (TRE) is not a strong prognostic factor, according to a study ...

In our series, 155 of 404 adults (38%) and 4 of 73 children (5%) with nonpilocytic gliomas had IDH1 mutations (P<0.001). We did not find IDH2 mutations in tumors in children. We also found that ...

In the largest-ever study of its kind, an analysis of entire tumor genomes has provided the most complete picture yet of an ...